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Abstract
Aims/hypothesis The aim of this study was to identify the
contribution of small- and large-fibre neuropathy to erectile
dysfunction in men with type 1 diabetes mellitus.
Methods A total of 70 participants (29 without and 41 with
erectile dysfunction) with type 1 diabetes and 34 age-matched
control participants underwent a comprehensive assessment
of large- and small-fibre neuropathy.
Results The prevalence of erectile dysfunction in participants
with type 1 diabetes was 58.6%. After adjusting for age,
participants with type 1 diabetes and erectile dysfunction had a
significantly higher score on the Neuropathy Symptom Profile
(mean ± SEM 5.3 ± 0.9 vs 1.8 ± 1.2, p = 0.03), a higher
vibration perception threshold (18.3 ± 1.9 vs 10.7 ± 2.4 V,
p = 0.02), and a lower sural nerve amplitude (5.0 ± 1.1 vs
11.7 ± 1.5 mV, p = 0.002), peroneal nerve amplitude (2.1 ± 0.4
vs 4.7 ± 0.5 mV, p < 0.001) and peroneal nerve conduction
velocity (34.8 ± 1.5 vs 41.9 ± 2.0 m/s, p = 0.01) compared with
those without erectile dysfunction. There was also evidence of a
marked small-fibre neuropathy with an impaired cold threshold
(19.7 ± 1.4°C vs 27.3 ± 1.8°C, p = 0.003), warm threshold
(42.9 ± 0.8°C vs 39.0 ± 0.9°C, p=0.005) and heart rate variability
(21.5 ± 3.1 vs 30.0 ± 3.7 beats/min, p = 0.001) and reduced
intraepidermal nerve fibre density (2.8 ± 0.7 vs 5.9 ± 0.7/mm,
p = 0.008), corneal nerve fibre density (12.6 ± 1.5 vs
23.9 ± 2.0/mm2, p < 0.001), corneal nerve branch density
(12.7 ± 2.5 vs 31.6 ± 3.3/mm2, p < 0.001) and corneal
nerve fibre length (8.3 ± 0.7 vs 14.5 ± 1.0 mm/mm2,
p < 0.001) in participants with type 1 diabetes and erectile
dysfunction. Erectile dysfunction correlated significantly
with measures of both large- and small-fibre neuropathy.
Conclusions/interpretation Small-fibre neuropathy is promi-
nent in patients with type 1 diabetes, and is associated with
erectile dysfunction and can be objectively quantified using
corneal confocal microscopy. This may allow the identifica-
tion of patients who are less likely to respond to conventional
therapies such as phosphodiesterase type 5 inhibitors.
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Introduction
Erectile dysfunction in patients with type 1 diabetes mellitus
poses a major clinical problem and was associated with poorer
diabetes-related quality of life in the DCCT/Epidemiology of
Diabetes Interventions and Complications (EDIC) cohort,
particularly in those with other complications including
neuropathy [1]. It is principally mediated by impaired
cavernosal vasodilatation due to a non-adrenergic,
non-cholinergic nerve signalling defect, penile endothelial
dysfunction and veno-occlusive disease; however, the relative
contributions of each may differ between type 1 and type 2
diabetes [2].
Most earlier studies have primarily reported on erectile
dysfunction in men with type 2 diabetes, and have demonstrated
abnormalities in quantitative sensory testing (QST) results
and sympathetic skin responses [3–7]. Recent studies in
participants with type 1 diabetes from the DCCT and EDIC
cohorts have also shown that cardiovascular autonomic
neuropathy and peripheral neuropathy are major risk factors for
erectile dysfunction [8, 9]. Furthermore, failure of erectile
dysfunction therapy has been attributed to severe erectile
dysfunction at presentation, worsening of endothelial
dysfunction and the presence of a significant neuropathy
[10, 11].
QST can identify small-fibre neuropathy; however, its
subjective nature and high variability has limited its wider
use. The Neuropathic Pain Specialist Interest Group
consensus statement on QST cautions on the interpretation
of results in relation to the clinical context [12]. More
objective measures of small-fibre neuropathy include skin
biopsy with assessment of intraepidermal nerve fibre density
(IENFD), but this procedure is invasive, requires considerable
laboratory expertise for analysis and has not been evaluated in
patients with erectile dysfunction. Corneal confocal
microscopy (CCM) is a rapid, non-invasive ophthalmic
examination technique that objectively evaluates small-fibre
neuropathy in patients with diabetes [13, 14] and is
comparable with skin biopsy in the diagnosis of diabetic
neuropathy [15, 16].
In this study, we undertook a comprehensive assessment of
small- and large-fibre neuropathy to delineate the neuropathy
status of an unselected cohort of men with type 1 diabetes in
relation to erectile dysfunction.
Methods
Participant selection We assessed 70 consecutive men with
type 1 diabetes from the Central Manchester University
Hospital Diabetes Centre and 34 age-matched healthy
control participants. No formal power calculations could be
undertaken as there are no previous studies evaluating
small-fibre damage using IENFD or CCM inmenwith erectile
dysfunction. The control group comprised healthy volunteers
without diabetes mellitus who were taking no regular
medication for any other comorbidity. These participants
were relatives and friends of the study participants or
University of Manchester staff, students and their relatives
and friends. Men with type 1 diabetes were recruited and
assessed from January 2009 to July 2014. All participants
completed the study. Exclusion criteria were any history of
neuropathy due to a non-diabetic cause, current or active
diabetic foot ulceration, and any history of corneal trauma or
surgery or a history of ocular disease or of a systemic disease
that might affect the cornea. The Central Manchester Research
and Ethics Committee approved this study, and written
informed consent was obtained from all individuals prior
to participation. This research adhered to the tenets of the
declaration of Helsinki.
Erectile dysfunction Patients were assessed using the
Neuropathy Symptom Profile (NSP), which specifically
defines erectile dysfunction as the ‘inability to have sexual
erection which is not due to medication or prostate surgery’
[17].
Assessment of neuropathy All study participants
underwent assessment of BMI, BP, HbA1c, lipid profile
(total cholesterol, LDL-cholesterol, HDL-cholesterol and
triacylglycerol) and eGFR (calculated by the abbreviated
Modification of Diet in Renal Disease [MDRD] equation:
186 × (creatinine / 88.4)−1.154 × (age)−0.203 × (0.742 if
female) × (1.210 if black). The NSP was used to assess the
symptoms of peripheral neuropathy. Neurological deficits were
evaluated using the modified Neuropathy Disability Score,
which is comprised of vibration perception, pinprick,
temperature sensation and the presence or absence of ankle
reflexes [18]. The vibration perception threshold (VPT) was
tested using a Horwell Neurothesiometer (Scientific
Laboratory Supplies, Wilfrod, Nottingham, UK). Cold (CT)
and warm (WT) perception thresholds were established on
the dorsolateral aspect of the left foot (S1) using the TSA-II
NeuroSensory Analyser (Medoc, Ramat-Yishai, Israel).
Electrodiagnostic studies were undertaken using a Dantec
Keypoint system (Dantec Dynamics, Bristol, UK) equipped
with a DISA temperature regulator to keep the limb
temperature constantly at 32–35°C. Sural sensory nerve
amplitude, sural sensory nerve conduction velocity, sural
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sensory nerve latency, peroneal motor nerve amplitude,
peroneal motor nerve latency and peroneal motor nerve
conduction velocity were assessed by a consultant
neurophysiologist. The motor nerve study was performed
using silver/silver chloride surface electrodes at standardised
sites defined by anatomical landmarks, and recordings
for the sural sensory nerve were taken using antidromic
stimulation over a distance of 100 mm. Deep breathing heart
rate variability (DB-HRV) was assessed using an ANX 3.0
autonomic nervous system monitoring device (ANSAR
Medical Technologies, Philadelphia, PA, USA).
Skin biopsy A 3 mm punch skin biopsy was taken from the
dorsum of the foot, approximately 2 cm above the second
metatarsal head, under local anaesthesia (1% lidocaine).
Sections (50 μm) were stained using anti-human PGP9.5
antibody (Abcam, Cambridge, UK) and nerve fibres were
demonstrated using SG chromogen (Vector Laboratories,
Peterborough, UK). IENFD was quantified in accordance
with established criteria and expressed as number per
millimetre [16].
CCM Patients underwent a CCM examination (Heidelberg
Retinal Tomograph III Rostock Cornea Module; Heidelberg
Engineering, Heidelberg, Germany) as per our previously
established protocol [19]. Six non-overlapping images per
participant (three per eye) from the centre of the cornea were
selected and quantified in a masked fashion. Three corneal
nerve variables were quantified: corneal nerve fibre density
(CNFD; the total number of major nerves per square
millimetre of corneal tissue), corneal nerve branch density
(CNBD; the number of branches emanating from the major
nerve trunks per square millimetre of corneal tissue) and
corneal nerve fibre length (CNFL; the total length of all nerve
fibres and branches [millimetre per square millimetre] within
the area of corneal tissue). Analysis of corneal nerve
morphology was performed using automated software,
ACCMetrics (Manchester, UK) [20].
Statistical analysis Analysis was carried out using SPSS for
Mac (Version 19.0; IBM Corporation, New York, NY, USA).
All data are expressed as means ± SEM. Data were tested for
normality using the Shapiro–Wilk normality test and by
visualising the histogram and normal Q-Q plot. To assess
within- and between-group differences, we used one-way
ANOVA (non-parametric, Kruskal–Wallis test). ANCOVA
was used to make age-adjusted comparisons between
participants with type 1 diabetes with and without erectile
dysfunction. A significant p value was considered to be
<0.05 (post hoc; Tukey’s test).
Results
All participants underwent all assessments except for skin
biopsy, which was performed in 40 participants with type 1
diabetes and 21 control participants.
Control participants vs men with type 1 diabetes
Participants in the control group were age matched to those
with type 1 diabetes (45.4 ± 2.6 vs 46.2 ± 1.7 years, p = 0.77).
The prevalence of erectile dysfunction was 58.6% inmen with
type 1 diabetes, compared with 5.9% in age-matched control
participants. There were no differences in BMI, BP, smoking
or alcohol consumption between the two groups. Participants
with type 1 diabetes had a significantly higher HbA1c level
(7.7 ± 0.2% [58.9 ± 2.1 mmol/mol] vs 5.6 ± 0.1%
[37.9 ± 0.7 mmol/mol], p < 0.0001) and lower total
cholesterol (4.2 ± 0.1 vs 5.1 ± 0.1 mmol/l, p < 0.0001) and
LDL-cholesterol (2.1 ± 0.1 vs 2.9 ± 0.1 mmol/l, p < 0.001)
levels compared with control participants (Table 1). Patients
with type 1 diabetes also had significantly higher NSP scores
(3.9 ± 0.7 vs 0.2 ± 0.1, p < 0.001), Neuropathy Disability
Scores (3.6 ± 0.4 vs 0.7 ± 0.2, p < 0.0001) and VPT
(16.4 ± 1.6 vs 6.2 ± 0.9 V, p < 0.001) and lower sural nerve
amplitude (7.5 ± 1.0 vs 17.9 ± 1.5 mV, p < 0.001), sural nerve
conduction velocity (39.7 ± 1.1 vs 49.0 ± 0.6 m/s, p < 0.001),
peroneal nerve amplitude (3.1 ± 0.4 vs 6.2 ± 0.3 mV,
p < 0.001) and peroneal nerve conduction velocity
(37.5 ± 1.2 vs 48.8 ± 0.7 m/s, p < 0.001) compared with
control participants (Table 2). Furthermore, individuals with
type 1 diabetes had a significantly higherWT (41.4 ± 0.6°C vs
37.6 ± 0.7°C, p < 0.001) and a significantly lower CT
(22.7 ± 1.0°C vs 28.2 ± 0.4°C, p < 0.001), DB-HRV
(25.1 ± 2.4 vs 31.0 ± 2.2 beats/min, p < 0.001), IENFD
(4.3 ± 0.5 vs 10.5 ± 0.7/mm, p < 0.001), CNFD (16.9 ± 1.2
vs 30.1 ± 1.2/mm2, p < 0.001), CNBD (19.8 ± 2.0 vs
37.1 ± 2.7/mm2, p < 0.001) and CNFL (10.7 ± 0.6 vs
17.1 ± 0.6 mm/mm2, p < 0.001), compared with control
participants (Table 2).
Type 1 diabetes participants with and without erectile
dysfunction Type 1 diabetes participants without erectile
dysfunction were younger than those with erectile
dysfunction (41.8 ± 2.3 vs 57.1 ± 1.85 years) (Table 1).
There were no differences in BP, BMI, HbA1c and lipid
profile between the two groups, but eGFR was significantly
lower and the albumin/creatinine ratio significantly higher
(both p < 0.001) in participants with erectile dysfunction.
After adjusting for age, both groups had a comparable
HbA1c level. Patients with type 1 diabetes and erectile
dysfunction had a higher NSP score (5.3 ± 0.9 vs
1.8 ± 1.2, p = 0.03) and VPT (18.3 ± 1.9 vs 10.7 ± 2.4 V,
p = 0.02), and a lower sural nerve amplitude (5.0 ± 1.1 vs
11.7 ± 1.5 mV, p = 0.002), peroneal nerve amplitude
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Table 1 Background demographic factors and clinical variables for control participants vs participants with type 1 diabetes and no erectile dysfunction
vs participants with type 1 diabetes and erectile dysfunction
Characteristic Control participants
(n = 34)
Type 1 diabetes, no ED
(n = 29)
Type 1 diabetes, ED
(n = 41)
p value
Age (years) 45.4 ± 2.6 41.8 ± 2.3 57.1 ± 1.9
BP, systolic/diastolic (mmHg) 136.9 ± 3.0/75.2 ± 1.8 133 ± 3.1/70.5 ± 1.9 139 ± 3.9/73.2 ± 1.5 0.8/0.7
HbA1c (mmol/mol) 37.9 ± 0.7*** 62.3 ± 2.8 58.8 ± 3.0 0.7
HbA1c (%) 5.6 ± 0.1*** 7.9 ± 0.3 7.6 ± 0.3
Duration of diabetes (years)a – 28.8 ± 2.3 28.1 ± 1.8 0.8
BMI (kg/m2) 26.4 ± 0.6 26.8 ± 0.9 26.5 ± 0.7 0.7
Albumin/creatinine ratio (mg/mmol) 0.6 ± 0.3* 0.8 ± 0.2 6.4 ± 3.3 <0.001
eGFR (ml min−1 [1.73 m]−2) 85.2 ± 1.2 87.4 ± 1.4 66.6 ± 3.7 <0.001
Smoking (cigarettes/day) 0.3 ± 0.3 0.9 ± 0.6 1.2 ± 0.7 0.4
Alcohol (units/week) 6.9 ± 1.9 3.8 ± 1.4 7.2 ± 1.9 0.4
Total cholesterol (mmol/l) 5.1 ± 0.1*** 4.2 ± 0.2 4.1 ± 0.2 0.8
HDL-cholesterol (mmol/l) 1.4 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 0.6
Triacylglycerol (mmol/l) 1.5 ± 0.1* 1.3 ± 0.2 1.2 ± 0.1 0.9
LDL-cholesterol (mmol/l) 2.9 ± 0.1*** 2.1 ± 0.2 2.1 ± 0.1 0.9
ED, yes (%) 5.9 58.6 (all participants with diabetes)
Data are means ± SEM unless otherwise stated
aAdjusted for age using ANCOVA
*p < 0.05, ***p < 0.001 control participants vs men with type 1 diabetes mellitus
p value is for comparison between participants with and without erectile dysfunction
ED, erectile dysfunction




Type 1 diabetes, no ED
(n = 29)
Type 1 diabetes,
ED (n = 41)
p value
NSP (/38)a 0.2 ± 0.1*** 1.8 ± 1.2 5.3 ± 0.9 0.03
Neuropathy Disability Score (/10)a 0.7 ± 0.2*** 2.8 ± 0.7 4.1 ± 0.6 0.1
VPT (V)a 6.2 ± 0.9*** 10.7 ± 2.4 18.3 ± 1.9 0.02
Sural nerve amplitude (μV)a 17.9 ± 1.5*** 11.7 ± 1.5 5.0 ± 1.1 0.002
Sural nerve conduction velocity (m/s)a 49.0 ± 0.6*** 42.6 ± 1.9 37.9 ± 1.4 0.07
Peroneal nerve amplitude (mV)a 6.2 ± 0.3*** 4.7 ± 0.5 2.1 ± 0.4 <0.001
Peroneal nerve conduction velocity (m/s)a 48.8 ± 0.7*** 41.9 ± 2.0 34.8 ± 1.5 0.01
CT (°C)a 28.2 ± 0.4*** 27.3 ± 1.8 19.7 ± 1.4 0.003
WT (°C)a 37.6 ± 0.7*** 39.0 ± 0.9 42.9 ± 0.8 0.005
IENFD (n/mm)a 10.5 ± 0.7*** 5.9 ± 0.7 2.8 ± 0.7 0.008
Automated CNFD (n/mm2)a 30.1 ± 1.2*** 23.9 ± 2.0 12.6 ± 1.5 <0.001
Automated CNBD (n/mm2)a 37.1 ± 2.7*** 31.6 ± 3.3 12.7 ± 2.5 <0.001
Automated CNFL (mm/mm2)a 17.1 ± 0.6*** 14.5 ± 1.0 8.3 ± 0.7 <0.001
DB-HRV (beats/min)a 31.0 ± 2.2*** 30.0 ± 3.7 21.5 ± 3.1 0.001
Data are means ± SEM
aAdjusted for age using ANCOVA
***p < 0.001, control participants vs men with type 1 diabetes mellitus
p value is for comparison between participants with and without erectile dysfunction
ED, erectile dysfunction
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(2.1 ± 0.4 vs 4.7 ± 0.5 mV, p < 0.001) and peroneal nerve
conduction velocity (34.8 ± 1.5 vs 41.9 ± 2.0 m/s, p = 0.01)
compared with participants without erectile dysfunction
(Table 2).
WT (42.9 ± 0.8°C vs 39.0 ± 0.9°C, p = 0.005) was
significantly higher in participants with erectile dysfunction
compared with those without, while CT (19.7 ± 1.4°C vs
27.3 ± 1.8°C, p = 0.003), DB-HRV (21.5 ± 3.1 vs 30.0 ± 3.7
beats/min, p = 0.001), IENFD (2.8 ± 0.7 vs 5.9 ± 0.7/mm,
p = 0.008), CNFD (12.6 ± 1.5 vs 23.9 ± 2.01/mm2, p < 0.001),
CNBD (12.7 ± 2.5 vs 31.6 ± 3.3/mm2, p < 0.001) and CNFL
(8.3 ± 0.7 vs 14.5 ± 1.0 mm/mm2, p < 0.001) were all
significantly lower (Figs 1, 2).
Erectile dysfunction correlated significantly with NSP
(r = 0.561, p < 0.001), Neuropathy Disability Score
(r = 0.452, p < 0.001), VPT (r = 0.619, p < 0.001), CT
(r = −0.488, p < 0.001),WT (r = 0.496, p < 0.001), sural nerve
amplitude (r = −0.655, p < 0.001), sural nerve conduction
velocity (r = −0.548, p < 0.001), peroneal nerve amplitude
(r = −0.685, p < 0.001), peroneal nerve conduction velocity
(r = −0.635, p < 0.001), IENFD (r = −0.603, p < 0.001),
CNFD (r = −0.641, p < 0.001), CNBD (r = −0.552,
p < 0.001) and CNFL (r = −0.657, p < 0.001).
There were no correlations between erectile dysfunction
and duration of diabetes (r = 0.012, p = 0.354), BMI
(r = −0.011, p = 0.926), BP (systolic, r = 0.025, p = 0.828;
diastolic, r = −0.004, p = 0.975), HbA1c (r = −0.174,
p = 0.169), total cholesterol (r = 0.020, p = 0.874),
HDL-cholesterol (r = −0.051, p = 0.689), LDL-cholesterol
(r = 0.001, p = 0.994) or triacylglycerol (r = −0.004,
p = 0.978).
Discussion
In this study, we have shown a high prevalence of erectile
dysfunction in men with type 1 diabetes mellitus, and
demonstrated large- and particularly small-fibre and autonomic
neuropathy in men with erectile dysfunction. The majority of
previous prevalence studies of erectile dysfunction have not
distinguished between type 1 and type 2 diabetes, and have in
fact focused primarily on individuals with type 2 diabetes [21].
However, data from the UroEDIC study showed that 55% of
men with type 1 diabetes had decreased libido and 34%
suffered from erectile dysfunction [22]. In another study of
men with type 1 diabetes mellitus, the self-reported erectile
dysfunction prevalence was 47.1% among those aged 43 years
or older [23]. Age and the duration of diabetes may affect the
prevalence of erectile dysfunction and, of course, differences
in diagnosing erectile dysfunction and in population
characteristics may also be partly responsible for the variability
in reported prevalence rates, which range from 35% to 75%
[21, 24]. While the duration of diabetes, poor glycaemic
control, hypertension, hyperlipidaemia and obesity have
previously been associated with erectile dysfunction in men
with type 2 diabetes [25], our study in type 1 diabetes did not
find a correlation between erectile dysfunction and HbA1c,
BMI, hypertension or duration of diabetes. The long duration
of diabetes in our study population and the use of a single
HbA1c measurement, as opposed to an average life-time value,
limit the relevance of this study to a wider population of men
with type 1 diabetes. Nonetheless, the long duration of diabetes
and the age of the men in this study are typical of those at
greatest risk of erectile dysfunction.
Fig. 1 IENFD (a) and CCM
(b–d) data from control
participants, men with type 1
diabetes mellitus with normal
erectile function and men with
type 1 diabetes mellitus with
erectile dysfunction. Data are
means ± SEM. ED, erectile
dysfunction; T1D, type 1 diabetes
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Although erectile dysfunction has previously been shown
to correlate with age and the presence of symptomatic
peripheral and autonomic neuropathy [23, 24], vascular
function has been investigated more often than neuropathy
as a means of identifying patients who may be more or less
responsive to treatment. In men with peripheral neuropathy,
sensory impulses from the shaft and glans of the penis to the
reflexogenic erectile centre and pudendal nerve innervation of
the pelvic floor muscles are impaired. This limits contraction
of the bulbocavernous and ischiocavernosus muscles, which
normally contribute to reduced venous outflow from the
cavernous bodies and maintenance of an erection [21]. As
parasympathetic activity is involved in achieving an erection,
autonomic neuropathy is strongly associated with erectile
dysfunction [21]. Furthermore, nitric oxide plays a key role
in maintaining penile erection, and is synthesised and released
via both the endothelium and autonomic nerves of the penile
arteries and corpus cavernosum [26].
Certain populations are less responsive to phosphodiesterase
type 5 (PDE5) inhibitor therapy, which is the first-line
treatment in the management of erectile dysfunction [27].
These include patients with severe diabetic neuropathy, and
those with neurological damage from procedures such as
radical prostatectomy and severe vascular disease [11, 27].
PDE5 inhibitors require a minimum amount of nitric oxide
production, which is not possible with severely damaged
nerves. It has been suggested that therapeutic strategies to
promote nitric oxide synthesis and availability may improve
erectile function and increase the effectiveness of PDE5
inhibitors in patients who are currently less responsive to such
therapies [27].
In a large study of 341 participants with erectile
dysfunction, peripheral neuropathy was identified in 38% of
individuals with diabetes and 10% of non-diabetic participants
using nerve conduction studies and QST [4]. Among those
individuals who had a vasculogenic basis for their erectile
dysfunction, the nocturnal tumescence test indicated that the
majority also had neuropathy [4]. Others researchers have
found impaired thermal thresholds, capsaicin-induced sensory
axon-reflex vasodilatation and sural nerve amplitude in men
with erectile dysfunction [5, 6]. Bleustein et al. undertook
QST of the penis and showed that non-diabetic participants
with erectile dysfunction had impaired thermal thresholds and
VPTs, and that participants with type 1 diabetes and erectile
dysfunction had a large- and small-fibre neuropathy [7]. This
is consistent with our finding of significant large- and
small-fibre neuropathy in participants with type 1 diabetes
with erectile dysfunction compared with those without
erectile dysfunction and control participants. More specific
neurological evaluations for erectile dysfunction can include
measuring the bulbocavernosus reflex, penile thermal sensory
thresholds and somatosensory evoked potentials, and
conducting corpus cavernosum electromyography. However,
these are highly specialised tests that lack reproducibility,
with no age-adjusted normal values to aid in diagnosis.
Nonetheless, the central role of small-fibre dysfunction is
evidenced by a previously reported strong correlation between
penile thermal sensory testing and the clinical evaluation of
erectile dysfunction [28], and by a lack of correlation between
neurophysiology and erectile dysfunction severity, as
determined using the International Index of Erectile
Function [8].
In the current study, we have demonstrated widespread
small-fibre damage, as evidenced by a reduction in IENFD
in foot skin biopsies and the observation of corneal nerve fibre
abnormalities using CCM in participants with type 1 diabetes
and erectile dysfunction. Indeed, we have previously
demonstrated the very high sensitivity and specificity of
CCM in identifying diabetic autonomic neuropathy [29].
Furthermore, IENFD and CCM abnormalities correlated with
erectile dysfunction. However, IENFD is invasive and cannot
be routinely deployed in the diagnostic work-up of patients
with erectile dysfunction. CCM, on the other hand, is a
non-invasive objective method with which to quantify
small-fibre damage, using an unbiased automated image
analysis technique [30, 31] that has previously been reported
to correlate with IENFD [15] and, in the present study,
correlated significantly with erectile dysfunction. However, a
range of small-fibre abnormalities are seen in patients with
erectile dysfunction. Therefore, the next step would be to
assess whether patients with more severe small-fibre damage
are less likely to respond to therapy for erectile dysfunction.
The diagnosis and management of erectile dysfunction in
men with diabetes is challenging, with a greater failure rate of
erectile dysfunction therapies than in the non-diabetic
population [32]. The identification of more extensive
small-fibre damage using CCMmay allow us to identify those
patients with erectile dysfunction who are less likely to
b caFig. 2 CCM images of the
corneal sub-basal nerves of:
(a) a control participant;
(b) a participant with type 1
diabetes mellitus and no erectile
dysfunction; and (c) a participant
with type 1 diabetes mellitus and
erectile dysfunction. Scale bar,
50 μm
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respond to conventional therapies such as PDE5 inhibitors,
and who should therefore be considered for daily or higher
doses of PDE5 inhibitors, combination therapies or, indeed,
alternative therapies such as intraurethral alprostadil or a
penile prosthesis [33, 34].
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